Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $5.7 million.

  • Corvus Pharmaceuticals' Accumulated Expenses rose 3572.95% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 3572.95%. This contributed to the annual value of $3.7 million for FY2024, which is 617.13% down from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Accumulated Expenses is $5.7 million, which was up 3572.95% from $5.0 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Accumulated Expenses high stood at $8.6 million for Q3 2022, and its period low was $3.7 million during Q4 2024.
  • For the 4-year period, Corvus Pharmaceuticals' Accumulated Expenses averaged around $5.2 million, with its median value being $4.6 million (2023).
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Accumulated Expenses crashed by 4740.33% in 2023, and later surged by 3572.95% in 2025.
  • Quarter analysis of 4 years shows Corvus Pharmaceuticals' Accumulated Expenses stood at $7.5 million in 2022, then plummeted by 47.4% to $4.0 million in 2023, then fell by 6.17% to $3.7 million in 2024, then soared by 53.58% to $5.7 million in 2025.
  • Its Accumulated Expenses was $5.7 million in Q3 2025, compared to $5.0 million in Q2 2025 and $3.9 million in Q1 2025.